Howard Hughes Medical Institute

Universal Medical Announces 2023 Interim Results

Retrieved on: 
Thursday, August 24, 2023
Pressure, Maintenance, China Central Television, Bed, Continuity, Nephrology, Kidney, Hospital, University Medical Center Freiburg, Central Television, Canadian Rural Revitalization Foundation, Competition (economics), Howard Hughes Medical Institute, Internet, ROA, Acquisition, Patient, Profit margin, Specialty, Growth, United States Secretary of Labor, Diagnosis, Healthcare industry, R, ESG, ROE, Internal, Pharmaceutical industry, Nursing, Bank, PRC

HONG KONG, Aug 24, 2023 - (ACN Newswire) - Genertec Universal Medical Group Company Limited (the "Universal Medical" or "Company"; Stock Coke: 2666.HK) is pleased to announce the interim results for the six months ended 30 June 2023.

Key Points: 
  • HONG KONG, Aug 24, 2023 - (ACN Newswire) - Genertec Universal Medical Group Company Limited (the "Universal Medical" or "Company"; Stock Coke: 2666.HK) is pleased to announce the interim results for the six months ended 30 June 2023.
  • As at 30 June 2023, the number of consolidated medical institutions increased to 55 (including four Grade III Class A hospitals and 26 Grade II hospitals), with a capacity of 13,893 beds in total.
  • The performance contribution of this business segment mainly comes from providing hospital clients with life cycle management of medical equipment, medical devises sales and internet-based healthcare services.
  • In August 2023, the company acquired 85% equity interests of Casstar Medical Technology Wuxi Co., Ltd. ("Casstar") at the consideration of RMB467.5 million.

Postal Service Celebrates Wonders of the Microscopic World

Retrieved on: 
Thursday, August 10, 2023
Confocal, The Postal Service, Neuron, Hair, Pinterest, Collection, United States Postal Service, University, Thomas Taylor (microscopist), Newsroom, Partnership, Life, Post, Keith, American Philatelic Society, Eye, Howard Hughes Medical Institute, Pollen, Skull, Brain, Research, Element, Sale, History of the University of Maryland, College Park, United, Post office, USPS, Acorn barnacle, Nature, Laboratory, Confusion, Platform supply vessel, Mail, Tongue, News, Microscope, Amazon

CLEVELAND, Aug. 10, 2023 /PRNewswire/ -- A dedication ceremony for Life Magnified stamps was held today in partnership with the American Philatelic Society at the Great American Stamp Show in Cleveland. The 20 stamps feature otherworldly images of some of the smallest components of life as we know it.

Key Points: 
  • In this case, we have enlarged the images to postage-stamp size — that doesn't happen often," said Luke Grossmann, senior vice president of finance and strategy for the Postal Service.
  • As these stamps show, there are worlds to be explored, even at the microscopic level."
  • The Postal Service generally receives no tax dollars for operating expenses and relies on the sale of postage, products and services to fund its operations.
  • For more information about the Postal Service, visit usps.com and facts.usps.com .

The FNIH Awards 2023 Lurie Prize in Biomedical Sciences to Navdeep S. Chandel, Ph.D. and Vamsi Mootha, M.D.

Retrieved on: 
Thursday, August 10, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, GSK, Lurie Prize in Biomedical Sciences, DNA, FNIH, Broad Institute, Mitochondrion, Bangladesh Technical Education Board, Cancer, Howard Hughes Medical Institute, Physiology, Biomedical sciences, Mentorship, Systems biology, Inflammation, Genomics, Research, Harvard University, Feinberg School of Medicine, Science, Harvard Medical School, Lurie, Molecular biology, Global Smoke-Free Partnership Award, Protein, Molecular genetics, Common Wealth Award of Distinguished Service, Anne, Johns Hopkins University, Charles, Psychiatry, Wiley Interdisciplinary Reviews: Systems Biology and Medicine, Hospital, Organelle, Ageing, Solomon, Massachusetts General Hospital, Pharmacology, Gene, Vamsi Mootha, Disease, MIT, Dentistry, Nursing, Pharmaceutical industry, Chandel, DRS, Neuroscience, Biochemistry, Medicine

“Each of this year’s Lurie Prize recipients are breaking new ground in mitochondrial research,” said Dr. Julie Gerberding, President and CEO of the FNIH.

Key Points: 
  • “Each of this year’s Lurie Prize recipients are breaking new ground in mitochondrial research,” said Dr. Julie Gerberding, President and CEO of the FNIH.
  • Chandel and Mootha as this year’s Lurie Prize in Biomedical Sciences recipients.
  • The 2023 Lurie Prize will be awarded to both recipients at the FNIH 11th Annual Awards Ceremony on the evening of October 18, 2023, in Washington, D.C.
  • For more information about the Lurie Prize in Biomedical Sciences and a list of previous winners, please visit fnih.org/LuriePrize .

Discrimination Lawsuit Against Top Research Institution Moves Forward

Retrieved on: 
Wednesday, August 9, 2023
HHMI, Howard Hughes Medical Institute, Paratriathlon, Disability, Maryland Circuit Courts, Medical device, Nursing

"Dr. Cheung is universally recognized as a pioneering biologist," said Gary Gilbert, president of Gilbert Employment Law, who represents Dr. Cheung. "She's been credited with numerous breakthrough discoveries -- which is why HHMI selected her in 2008 to be one of just a few hundred HHMI investigators in the entire country, a distinction that comes with roughly $1 million in annual funding, and renewed her contract in 2013."

Key Points: 
  • The trial, scheduled to start December 4, 2023, has massive implications not just for the parties involved, but for millions of other Americans who, like Dr. Cheung, face employer discrimination due to their disability status.
  • "Dr. Cheung is universally recognized as a pioneering biologist," said Gary Gilbert, president of Gilbert Employment Law, who represents Dr. Cheung.
  • "My disability has made me a better and more passionate physician-scientist," said Dr. Cheung.
  • "I owe it to myself -- and my fellow researchers -- to speak up and hold institutions like HHMI accountable for blatant discrimination."

Dr. Igor Splawski Appointed as Chief Scientific Officer of Yarrow Biotechnology

Retrieved on: 
Friday, July 21, 2023
Research, Finance, Genetics, Banking, Professional Services, Biotechnology, Health, Pharmaceutical, Science, Myopathy, PNAS, Central nervous system, Biomedical Research, Novartis Institute for Tropical Diseases, Therapy, Executive director, University, NIBR, Investment, The W. Alton Jones Cell Science Center, Sofia University, Deafness, Infection, CureVac, Nature Genetics, Cancer, Howard Hughes Medical Institute, Boston, Multimedia, RNA, Doctor of Philosophy, CNS, Disorder, Messenger, Harvard Medical School, Human genetics, RTÉ Executive Board, Publication, Partner, Patient, Master of Science, The New England Journal of Medicine, RTW, Spectrum, Cardiomyopathy, Hospital, CVAC, Arrhythmia, Gene, III, Disease, Vaccine, Pharmaceutical industry, Achillea millefolium

Yarrow Biotechnology, Inc. (“Yarrow”), an RTW Investments, LP (“RTW”) -incubated company developing nucleic acid therapeutics and other modalities for severe, genetically defined diseases including those of the central nervous system (“CNS”), today announced the appointment of Dr. Igor Splawski as Chief Scientific Officer.

Key Points: 
  • Yarrow Biotechnology, Inc. (“Yarrow”), an RTW Investments, LP (“RTW”) -incubated company developing nucleic acid therapeutics and other modalities for severe, genetically defined diseases including those of the central nervous system (“CNS”), today announced the appointment of Dr. Igor Splawski as Chief Scientific Officer.
  • Prior to serving as Chief Scientific Officer of CureVac, Dr. Splawski spent fifteen years at the Novartis Institutes for BioMedical Research (NIBR).
  • Dr. Splawski has a PhD in Human Genetics from the University of Utah and an MSc in Biotechnology from Sofia University.
  • Splawski is recognized as a leading figure in the development of complex human genetic tests, protein biologics, and RNA therapies, and we are excited to welcome him to Yarrow,” said Peter Fong, PhD, Chief Executive Officer of Yarrow Biotechnology and Partner and Chief Development Officer at RTW.

Rapport Therapeutics Names Scientific Advisory Board

Retrieved on: 
Thursday, June 29, 2023
Health, Neurology, Other Science, Clinical Trials, Research, Science, Biotechnology, Molecular biology, Baylor University, Temperature, Howard Hughes Medical Institute, Genetics, Journal, National Academy of Medicine, Patient, Nervous system, Catalysis, RAPS, Eurosport 1, Royal Society, SAB, Nobel Prize, National academy, University, Emeritus, American Epilepsy Society, Janelia Research Campus, Royal, Princess of Asturias Awards, System, Scientific method, Safety, HHMI, Third Rock Ventures, FRS, Shaw Prize, Therapy, Epilepsy, Central nervous system, McMillan, RAP, NAS, Baylor College of Medicine, Nobel Prize in Chemistry, University of California, San Francisco, DSM-IV codes, American Academy, Buckingham Palace, Princeton University, Harvard Medical School, Nobel, United Kingdom, Nerve injury, Gene, Pharmaceutical industry, Chemistry, Rapport, Neuroscience, Pain, Physiology, Nature, Anatomy, Medicine

Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins to advance precision neuromedicines, today announced the formation of a scientific advisory board comprised of distinguished experts in medicinal chemistry, molecular pharmacology, neurobiology and epilepsy.

Key Points: 
  • Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins to advance precision neuromedicines, today announced the formation of a scientific advisory board comprised of distinguished experts in medicinal chemistry, molecular pharmacology, neurobiology and epilepsy.
  • Its members are David Julius, Ph.D., David MacMillan, Ph.D., David Clapham, M.D., Ph.D., Allan Basbaum, Ph.D., FRS and Jeffrey Noebels, M.D., Ph.D.
  • “Rapport has assembled what may well be the most impressive scientific advisory board in biotech, which includes some of the world’s most accomplished scientists,” said Steve Paul, M.D., Chairman of the Rapport Board of Directors, Co-Founder and Advisory Partner at Third Rock Ventures.
  • Dr. Clapham was HHMI’s vice president and chief scientific officer from 2016 to 2022.

The Jane Coffin Childs Fund for Medical Research Names its 2023 Fellows

Retrieved on: 
Tuesday, June 27, 2023
Fred Hutchinson Cancer Research Center, Child & Family Services Open, HHMI, Anxiety, Cancer, Biomedical Research, United States Air Force Scientific Advisory Board, Howard Hughes Medical Institute, Research, Disease, Multimedia, Science, Merck & Co., Jane Coffin Childs Memorial Fund for Medical Research, Jane, Health, Sleep, Fund, JCC, Memory, Medical research, Pharmaceutical industry, Management

NEW HAVEN, Conn., June 27, 2023 /PRNewswire/ -- The research landscape has changed greatly since the Jane Coffin Childs Fund for Medical Research (JCC) first awarded fellowships to postdoctoral scientists almost 80 years ago. What has remained constant is the quality and potential impact of the science it supports, and this year's class of fellows is no exception.

Key Points: 
  • NEW HAVEN, Conn., June 27, 2023 /PRNewswire/ -- The research landscape has changed greatly since the Jane Coffin Childs Fund for Medical Research (JCC) first awarded fellowships to postdoctoral scientists almost 80 years ago.
  • Twenty-seven new fellows were selected from a competitive field based on their doctoral research accomplishments, innovative research plans, and their chosen scientific mentors.
  • In total, over $7M is committed by the Jane Coffin Childs Fund and partners to the 2023 cohort of Fellows.
  • The Jane Coffin Childs Memorial Fund for Medical Research was established by the Childs Family in 1937, to honor the memory of Jane Coffin Childs.

TEXAS CHILDREN'S HOSPITAL'S DR. MARIA ELENA BOTTAZZI AWARDED THE VILCEK-GOLD AWARD FOR HUMANISM IN HEALTHCARE

Retrieved on: 
Tuesday, June 6, 2023
Vaccine, Humanism, COVID-19, Baylor University, Business, Howard Hughes Medical Institute, Woman, DRS, Global health, Research, Houston, Biology, Vilcek Foundation, Texas Children's Hospital, Bloomberg, Public Health Service Distinguished Service Medal, IndoVac, Tropical medicine, National school, Baylor College of Medicine, Corbevax, Hospital, Arnold, Pharmaceutical industry, Health care

HOUSTON, June 6, 2023 /PRNewswire/ -- Texas Children's Hospital is pleased to announce that Dr. Maria Elena Bottazzi, Co-Director of the Center for Vaccine Development at Texas Children's Hospital and Senior Associate Dean of the National School of Tropical Medicine at Baylor College of Medicine, received The Vilcek-Gold Award for Humanism in Healthcare for her work developing open-source, patent-free COVID-19 vaccine technology. The prestigious award, created jointly by The Arnold P. Gold Foundation and The Vilcek Foundation in 2019, recognizes a foreign-born individual who has had an extraordinary impact on humanism in healthcare through their professional achievements in the United States.

Key Points: 
  • The prestigious award, created jointly by The Arnold P. Gold Foundation and The Vilcek Foundation in 2019, recognizes a foreign-born individual who has had an extraordinary impact on humanism in healthcare through their professional achievements in the United States.
  • "It was a very emotional moment to learn that as a Honduran-trained biomedical scientist, I was the recipient of the Vilcek-Gold Award for Humanism in Healthcare.
  • I am very proud of this recognition, it encourages and empowers me even more to continue advocating for equity in global health," Dr. Bottazzi said.
  • Dr. Bottazzi has led numerous community events to educate Latinos about COVID-19 vaccine development and served on multiple local and national task forces.

Outpace Bio Expands Seattle Presence with Cell Therapy Research Hub & Collaborations with Leading Experts in Protein Design & Cancer Immunotherapy

Retrieved on: 
Monday, May 22, 2023
University, UW, Biochemistry, Fred Hutchinson Cancer Research Center, Infection, Clinical and Translational Science Award, Howard Hughes Medical Institute, Research, Doctor of Philosophy, Breakthrough Prize in Life Sciences, CAR, MD, Patient, Machine learning, University of Washington School of Medicine, Algorithm, Cancer, Drug discovery, Burke, Cell engineering, Therapy, Pharmaceutical industry, Oncology, Immunotherapy, Medicine

This expansion will accelerate the company’s efforts to turn cell therapies into safe and effective cures for patients.

Key Points: 
  • This expansion will accelerate the company’s efforts to turn cell therapies into safe and effective cures for patients.
  • "Seattle is home to some of the world's leading biomedical institutions, and we look forward to growing into this community," said Marc Lajoie , CEO and co-founder of Outpace Bio.
  • "Together, these collaborations will help advance our mission to create safe and effective cell therapies."
  • Dr. Baker has co-founded multiple biotechnology companies, published over 600 research articles, and is a named inventor on more than 100 patents related to protein design.

Colossal Biosciences and the Vertebrate Genomes Project Publish the First Near Complete African Elephant Chromosome Level Genome

Retrieved on: 
Thursday, May 18, 2023
Research, Pharmaceutical, Environmental Issues, Other Natural Resources, Agriculture, Natural Resources, Environment, Genetics, Science, Veterinary, Biotechnology, Health, VGL, African forest elephant, Colossal Biosciences, DNA, World Wide Fund for Nature, VGP, IUCN, Partnership, Vertebrate, Face, Survival, NCBI, Rockefeller University, Howard Hughes Medical Institute, Multimedia, Elephant, Biology, Biodiversity, Woolly mammoth, Climate change, Animal, Risk, Map, Love, Arima, Forest, Vertebrate Genomes Project, Death, WWF, News, Genome, Disease, Antibiotics, Hunting, African elephant, Colossal

Colossal Biosciences, a breakthrough biosciences and genetic engineering company, and the Vertebrate Genomes Project (VGP) , which aims to sequence high-quality reference genomes for all living vertebrates, partnered to successfully generate the first high-quality reference genome of the African elephant.

Key Points: 
  • Colossal Biosciences, a breakthrough biosciences and genetic engineering company, and the Vertebrate Genomes Project (VGP) , which aims to sequence high-quality reference genomes for all living vertebrates, partnered to successfully generate the first high-quality reference genome of the African elephant.
  • Last year, the partnership announced a near complete sequence of the Asian elephant genome.
  • View the full release here: https://www.businesswire.com/news/home/20230518005164/en/
    African elephant image and genome assembly statistics; sequencing and assembly platforms used with genome coverage fold; Arima Hi-C assembly map.
  • The VGP and Colossal are seeking help with sample donors to produce a high-quality reference genome of the Forest Elephant.